InspireMD Receives FDA Approval for CGUARDIANS III Pivotal Study of SwitchGuard Neuro Protection System
Key Insights
The FDA has approved InspireMD's Investigational Device Exemption application to initiate the CGUARDIANS III pivotal study of its SwitchGuard neuro protection system (search) for stroke (search) prevention.
The study will evaluate next-generation enhancements to the SwitchGuard system for use with the CGuard Prime 80 cm stent platform in transcarotid artery revascularization procedures.
InspireMD targets a U.S. commercial launch of the SwitchGuard NPS in 2027, pending regulatory approval following successful completion of the pivotal trial.
InspireMD has received FDA approval for its Investigational Device Exemption (IDE) application to initiate the CGUARDIANS III pivotal study of its SwitchGuard neuro protection system (search) (NPS). The approval marks a significant milestone for the company's stroke (search) prevention technology, incorporating next-generation enhancements from prior IDE approval for use with its CGuard Prime 80 cm stent platform in transcarotid artery revascularization (TCAR) procedures.
The CGUARDIANS III trial will be led by Patrick Geraghty, M.D., professor of surgery and radiology in the section of vascular surgery at Washington University School of Medicine in St. Louis, Missouri, and Patrick Muck, M.D., program director and chief of vascular surgery at Good Samaritan Hospital in Cincinnati, Ohio. Both physicians previously served as co-lead investigators for the CGUARDIANS II trial and will continue in these roles for the new study.
Clinical Development Strategy
"The approval of our CGUARDIANS III IDE represents a meaningful advancement in our quest to offer the full TCAR tool kit leveraging our best-in-class CGuard Prime 80 cm stent platform for unmatched stroke (search) prevention and carotid disease management," said Marvin Slosman, CEO of InspireMD. The company is targeting a U.S. commercial launch of the SwitchGuard NPS in 2027, contingent upon regulatory approval.
Technology Platform
InspireMD's approach centers on its proprietary MicroNet mesh technology, which the company aims to establish as the industry standard for carotid stenting. The technology is designed to provide outstanding acute results and durable, stroke (search)-free long-term outcomes for patients undergoing carotid interventions.
The CGUARDIANS III study builds upon the foundation established by the previous CGUARDIANS II trial, with the new study incorporating enhanced features of the SwitchGuard neuro protection system (search). The trial is registered under clinical trial identifier NCT07277296.
Market Position
InspireMD positions itself as a developer focused on stroke (search) prevention through advanced carotid stent systems. The company's CGuard Prime carotid stent system (search) represents its flagship technology for preventing stroke in patients with carotid artery disease (search). The addition of the SwitchGuard neuro protection system (search) is intended to provide a comprehensive toolkit for TCAR procedures.
The company's stock trades on Nasdaq under the ticker symbol NSPR, and it maintains an active investor relations program to communicate developments to stakeholders.